Intravenous magnesium does not influence the activity of the coagulation cascade.

What Was Tested

Researchers studied Magnesium in this randomized controlled trial publication.

The researchers therefore evaluated the effect of intravenous magnesium on prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin III complex (TAT) concentrations, and fibrin degradation products (FbDP) in a randomized, cross-over study in 14 healthy volunteers.

Citrated blood samples were collected at 0, 30, and 180 min.

Who Took Part

The abstract describes 14 volunteers taking part.

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

The design is described as randomized, placebo-controlled and crossover.

The volunteers were allocated by chance, so the Magnesium group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Magnesium group a baseline to be compared against.

Each person switched between Magnesium and the comparison at some point, usually with a gap in between.

What Was Measured

The researchers therefore evaluated the effect of intravenous magnesium on prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin III complex (TAT) concentrations, and fibrin degradation products (FbDP) in a randomized, cross-over study in 14 healthy volunteers.

Topics PubMed links to this paper include Blood Coagulation and Magnesium.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Magnesium in 14 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2001 (Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis), a journal based in England.

More context: the related Vitamin D, K2, Magnesium and Zinc library page, all human trials.